Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine and Capecitabine vs Capecitabine for Biliary Tract Cancer
NCT03779035Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in biliary tract cancer (BTC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease-Free Survival at 24 months. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03779035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779035.